Biotech & Genomics

Investment Thesis

CRISPR-based gene editing has achieved its first commercial cures in sickle cell disease and beta-thalassemia, demonstrating clinical proof-of-concept for genetic medicine after two decades of research. mRNA platform technology developed during COVID-19 is being repurposed for personalized cancer vaccines, rare disease treatment, and respiratory pathogens, compressing development timelines. AI-driven protein structure prediction is accelerating drug discovery across therapeutic areas and reducing the cost of early-stage research.

Theme Score Breakdown

Biotech & Genomics scores low Moderate because the scientific breakthroughs are real but the investment return requires navigating binary clinical risk at scale. CRISPR cures for sickle cell and beta-thalassemia are genuine achievements, but at $2-4 million per treatment for very rare conditions, revenue visibility scores only 8 even for commercial approvals. The investable universe scores 6 because the theme ranges from quality large-cap biopharmaceuticals to highly speculative single-program development companies where financial data is minimal and liquidity is thin. The -6 penalty reflects the combination of clinical binary risk, manufacturing complexity, and IRA pricing pressure that has reduced expected commercial upside for durable treatments. This theme sits below GLP-1 because it lacks the proven commercial revenue and clear near-term market that NVO and LLY have already demonstrated.

Key Risks

• Clinical trial failures are binary events that can wipe 80-90% of value from single-program companies
• Drug pricing pressure from government negotiations under IRA reducing biotech revenue ceiling
• Gene therapy manufacturing complexity and high cost limiting addressable patient populations
• Most pipeline companies are pre-revenue; the theme requires tolerance for significant speculative exposure